



Amneal Pharmaceuticals

Jefferies Healthcare Conference
Company Presentation



June 5, 2025



Cautionary statement on forward looking statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as "plans," "expects," "will," "anticipates," "estimates," and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; the imposition of tariffs may adversely affect our business, results of operations and financial condition; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our dependence on third-party agreements for a portion of our product offerings; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our class A common stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

NON-GAAP FINANCIAL MEASURES


This presentation includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted operating cash flow and net leverage, which are intended as supplemental measures of the Company's performance that are not required by or presented in accordance with GAAP. Adjusted diluted EPS reflects diluted earnings per share based on adjusted net income, which is net income (loss) adjusted to (A) exclude (i) non-cash interest, (ii) GAAP provision for income taxes, (iii) amortization, (iv) stock-based compensation, (v) acquisition, site closure expenses, and idle facility expenses, (vi) restructuring and other charges, (vii) charges related to certain legal matters, including interest, net, (viii) asset impairment charges, (xiv) increase in tax receivable agreement liability, (x) other and (xi) net income attributable to non-controlling interests, and (B) include non-GAAP provision for income taxes. Non-GAAP adjusted diluted EPS for the three months March 31, 2025 and 2024 and year ended December 31, 2024 was calculated using the weighted average fully diluted shares outstanding of Class A common stock. Adjusted EBITDA reflects net income (loss) adjusted to exclude (i) interest expense, net, (ii) provision for (benefit from) income taxes, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) acquisition, site closure, and idle facility expenses, (vi) restructuring and other charges, (vii) loss on refinancing (viii) charges related to legal matters, net, (ix) asset impairment charges, (x) foreign exchange loss (gain), (xi) change in fair value of contingent consideration, (xii) (insurance recoveries) charges for property losses and associated expenses, net, (xiii) regulatory approval of milestone, (xiv) amortization of upfront payment, (xv) increase (decrease) in tax receivable agreement liability, (xvi) reorganization expense, and (xvii) other. Net leverage is calculated as the total outstanding principal on the Company's debt less cash and cash equivalents, divided by adjusted EBITDA for the last twelve months or year ended, as applicable. Adjusted operating cash flow reflects cash flow from operations excluding discrete items such as legal settlement payments. Management uses these non-GAAP measures internally to evaluate and manage the Company's operations and to better understand its business because they facilitate a comparative assessment of the Company's operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company's operations and underlying operational performance. The compensation committee of the Company's board of directors also uses certain of these measures to evaluate management's performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company's financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company's financial performance, results of operations and trends while viewing the information through the eyes of management. These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company's financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company's GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included in the appendix, and should not rely on any single financial measure to evaluate the Company's business. A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth herein.

Entering a new chapter of growth in 2025 and beyond

2019 – 2024:

DIVERSIFIED BUSINESS AND EXPANDED PORTFOLIO

- Drive sustainable long-term growth through superb execution, innovation, and tuck-in business development
- Demonstrated ability to execute our strategic plan and deliver strong financial performance and de-leverage



2025 & BEYOND (1):


NEW ERA OF GROWTH AS A GLOBAL BIOPHARMACEUTICAL COMPANY

- Growing CREXONT® for Parkinson's Disease, Brekiya® (DHE autoinjector) for migraine and cluster headache and other Specialty assets
- Advance Biosimilars pipeline
- Expanding in high-growth areas such as GLP-1 / Peptides
- Leveraging our proven track record of innovation, high quality, strong execution and outstanding customer service in these new areas of growth

(1) Any expected launch is subject to certain assumptions and factors, many of which are out of our control, such as regulatory approval, and as such, may be subject to change. For more information, please refer to Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K.


Successful transformation and track record of success: Diversification, growth and deleveraging to create value

	2019	2025[1]
Net Revenues	$1.6B -2%	$3.0 - $3.1B +7% to +11%
Increased Diversification Oral solid generics % of total revenue	53%	23%
Deep Pipeline Pending ANDAs (% non-oral solids) Pipeline products (% non-oral solids) Biosimilars	97 (44%) 80 (64%) 3 pipeline	81 (65%) 47 (96%) 3 commercial + 5 pipeline
Adjusted EBITDA[2]	$339M	$650M - $675M +4% to +8%
Operating Cash Flow	$2M	$255M - $285M
Net Leverage[2]	7.4x	3.9x



(1) Reflects Full Year 2025 Guidance for Net Revenues, Adjusted EBITDA and Operating Cash Flow; Other metrics as of Q1 2025.
(2) Adjusted EBITDA and Net Leverage are non-GAAP measures. Refer to non-GAAP reconciliations in the Q1'25 earnings presentation.
Note: Growth percentages reflect comparisons to prior year.

Strong and sustainable revenue growth and profitability driven by all business areas



- **Net Revenue +11%** from 2019 to 2024 CAGR
- **Adjusted EBITDA +13%** from 2019 to 2024 CAGR

Note: Totals may not add due to rounding.
(1) Affordable Medicines includes Retail Generics, Injectables, Biosimilars and International net revenues.
(2) New launches reflects new product launches since 2019 and biosimilars.
(3) Adjusted EBITDA is a non-GAAP measure. Refer to the non-GAAP reconciliation in the Q1 earnings presentation for 2019-2024 adjusted EBITDA.

Formula for sustainable long-term revenue growth

Segment	2024 Revenue	Strategy for Growth	Growth Projection[2]
Affordable Medicines[1]	$1.685B	Leading retail and injectables portfolio with durable and impactful complex products including 505(b)(2) injectables; ongoing cadence of new product launches, expanding biosimilars portfolio and international expansion	High single-digits
Specialty	$446M	Grow specialty branded portfolio focused on Neurology (CREXONT®, RYTARY®, ONGENTYS® and Breykia® DHE autoinjector) and Endocrinology (UNITHROID®)	High single-digits $500M+ revenue by 2027
AvKARE	$663M	Grow across distribution, government and institutional channels driven by new product launches	Double-digits $900M+ revenue by 2027
Total Company	$2.794B	Sustainable growth driven by all aspects of our diversified and expanding portfolio	High single-digits



(1) Affordable Medicines includes Retail Generics, Injectables, Biosimilars and International net revenues.
(2) Growth projection reflects the potential outcomes of delivering our long-term strategy and is based on the current macro environment and expected product pipeline launches, among other assumptions.

Delivering innovations in increasingly complex areas of medicine



Amneal founded
New Jersey



Acquires InterPharm
New York



Started India Operations



Inserts / Implants
New York



Injectables
India



Nasal sprays
New Jersey



Transdermal patches
New Jersey

acquisition



ALYMSYS®
(bevacizumab)



RELEUKO®
(filgrastim)



FYLNETRA®
(peg-filgrastim)



Naloxone HCL Nasal Spray
(Anti-overdose)



Breykia®
(DHE Autoinjector)
(Migraine & Cluster Headache)



INHALATION

2 GLP-1 sites operational
India

2002 | 2005 | 2008 | 2011 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | 2027E | 2028E

Oral solids
New Jersey



Oral liquids
New Jersey



Topicals
New Jersey



Inhalation
Ireland



Combination
Form public company

amneal PHARMACEUTICALS + Impax

Ophthalmics
India



International expansion
First partnerships & approvals

CREXONT®
(Parkinson's)

1st Injectable RTU 505(b)(2)

First generic GLP-1



2 denosumab & 2 peg-filgrastim biosimilars

Xolair biosimilar

Note: Reflects the timing of when a new product in each category was initially launched or is expected to launch by Amneal. Any such expected launch is subject to certain assumptions and factors, many of which are outside our control, such as regulatory approval, and as such, may be subject to change. For more information, please refer to Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. All trademarks are property of their respective owners.

Our R&D and manufacturing capabilities are a competitive advantage with one of the largest U.S. manufacturing footprints in the industry

Strong R&D and manufacturing capabilities delivering complex & high-value dosage forms



INJECTIBLES & STERILE

- Peptides (including GLP-1) and API
- Sterile Fill Finish
- Microspheres
- Liposomes
- General and Oncology Injectables



TRANSDERMALS

- Matrix
- Hydrogel
- Form Fill Seal
- Hormonals



ORAL SOLIDS, LIQUIDS & TOPICALS

- IR/ER tablets
- Hard and Softgel Capsules
- Oral liquids
- Creams



OPHTHALMICS & OTICS

- Solutions
- Suspension
- Emulsion



INHALATION


- Metered Dose
- Dry Powder
- Nasal Spray Pumps
- Blow Fill Seal Inhalation



DEVICES

- Rings
- Autoinjectors

Global network of FDA-approved, cGMP manufacturing sites



- Co-located manufacturing and R&D centers **maximize efficiency**
- **In-house API capabilities**
- Constructing **two large-volume manufacturing facilities** for peptide synthesis & sterile fill-finish production
- Internally operated facilities help maintain **control of the supply chain**
- Trusted manufacturer with **track record of delivering best-in-class quality**

Expanding specialty business with new therapeutic offerings

Specialty highlights
Expanding portfolio

- Therapeutic focus today on **Neurology (Parkinson's Disease and migraine) and Endocrinology**
- **Successful commercialization of CREXONT®** for Parkinson's Disease
- **Approval of Breyika® (DHE autoinjector)** for Migraine and Cluster Headache
- Well-positioned to add **more Specialty products** through pipeline & business development

Continued Specialty growth
CREXONT building momentum

- **$449M Specialty revenue** in LTM Q1 2025, **growing +11%** compared to prior year period

Revenue $ millions	Q1 2025	% Growth
RYTARY®	$44	(10%)
CREXONT®	$9	NM
UNITHROID®	$33	+14%
All Other	$22	(18%)(1)
Total Specialty	**$108**	**+3%**

Next Growth Drivers
Launches & near-term pipeline

Timing	Program	Therapeutic Area
Launched Q1 2024	ONGENTYS®	Parkinson's Disease
Launched Sept. 2024	CREXONT®	Parkinson's Disease
Approved; 2H'25 launch	DHE Autoinjector	Migraine and Cluster Headache

(1) Reflects $4 million of out-licensing revenue in the prior year period.

Strong adoption of CREXONT® for Parkinson's Disease

CREXONT® on-track to be leading branded therapy

for growing Parkinson's patient population


- **1M+ U.S. Parkinson's Disease (PD) patient population, ~700K PD patients on CD/LD therapy, and 90K+ new diagnoses each year** with one new PD patient diagnosed every six minutes[1]
- **Longest-lasting oral CD/LD formulation available** due to innovative formulation combining IR and ER with novel technology designed to target area of absorption in the body
- **Market share at over 1% today and expect 3%+ by year-end**, ahead of our expectations and RYTARY's launch, signaling physician confidence and adoption momentum
- **Increased coverage to ~60% in April**, up from ~30% in Dec 2024, with addition of several formularies: Veterans Administration, UnitedHealthcare, CVS Health and Cigna Commercial; **Expect over 70% coverage** as CREXONT coverage (% of covered lives and quality of insurance coverage) tracking well ahead of RYTARY

CREXONT® (carbidopa and levodopa) EXTENDED-RELEASE CAPSULES 35mg/140mg · 52.5mg/210mg 70mg/280mg · 87.5mg/350mg

Strong first year results

Ahead of expectations

CREXONT® PRESCRIPTION GROWTH (TRx)[2]
(Week Ending)



Expect $300-500M U.S. peak sales


(1) Stocchi F et al. Parkinsonism Relat Disord. 2014;20(2):204-211.
(2) Source: IQVIA weekly script data as of WE 5/23/25. Rx data for week ending 11/29/24, 12/27/24, and 1/3/25 reflects holiday impact.

Brekiya® (DHE autoinjector) is a new treatment for episodic migraine and cluster headache



DHE (dihydroergotamine mesylate) autoinjector
Self-administer with same medication used in hospitals

First and only autoinjector to deliver
the power of DHE for sustained* pain relief [4][5]†





Designed to be used **at any point during the attack** and may **protect patients from headache recurrence** [4][5]



Potential to provide the same powerful medication used in hospitals, in a **ready-to-use, single-dose autoinjector** [6]



Intended to deliver **one dose subcutaneously**, which may be helpful for patients who respond inadequately to oral therapies due to nausea/vomiting, gastroparesis, or delayed dosing [6]



Potential to give patients the ability to self-administer, with **no need for refrigeration, assembly, or priming the device**

Potential broad usage among patients who experience severe, treatment-resistant headaches

Expect $50-100M U.S. peak sales

(1) Cohen F, et al, "Prevalence and burden of migraine in the United States: A systematic review", Headache, 2024; (2) Lipton RB, et al, "Migraine in the United States Epidemiology and patterns of health care use", Neurology, 2002; (3) Per clinical trial data, around 20% of patients taking Ubrelvy and around 10% of patients taking Nurtec ODT would be considered "failures" as they would not experience pain relief at 2 hours post-dose compared to a placebo group. Using average of both to arrive at 15%; (4) Winner P, Ricalde O, Le Force B, Saper J, Margul B. *Arch Neurol.* 1996;53(2):180-184. doi:10.1001/archneur. 1996.00550020092020; (5) Mather PJ, Silberstein SD, Schulman EA, Hopkins MM. *Headache*. 1991;31(8):525-532. doi:10.1111/j.1526-4610.1991.hed3108525.x4; (6) Silberstein SD, Shrewsbury SB, Hoekman J. *Headache*. 2020;60(1):40-57. doi:10.1111/head.13700; * Sustained represents a duration of approximately 24-72 hours; † Cluster headache results reported using IV administration.

Strategic collaboration with Metsera represents a new, integrated business model to drive innovation at scale and speed in the GLP-1 space



Amneal is uniquely positioned to be a trusted and collaborative partner because of our expertise, scale and speed

Development

Amneal has leading capabilities from formulation design, peptide chemistry, drug-device development and CMC activities with **over 1,000 scientists**

Manufacturing

Constructing two new, world-class, large-volume manufacturing facilities for peptide synthesis and sterile fill-finish production, and leverage existing Amneal manufacturing sites

Commercialization

- **Metsera's preferred & majority supplier** in U.S., Europe and other markets
- Amneal granted **license to commercialize in ~20 emerging markets, including India**

(1) Estimated global GLP-1 market size per Grand View Research GLP-1 Receptor Agonist Market Size 2025 – 2030.
Note: CMC = Chemical, manufacturing and control.

Continued strength in Affordable Medicines driving sustainable growth

Retail

- **Diverse portfolio of complex retail products**
- **Ability to develop & commercialize complex products** driving portfolio shift towards high impact medicines for patients over time


Injectables

- **Expanding portfolio of 40+ institutional injectables** in durable and growing category, focused on shortage products[1]
- **Deep capabilities** across R&D, manufacturing and commercial **to drive this business at scale**

Biosimilars

- **Strong uptake of ALYMSYS®, RELEUKO® and FYLNETRA®:** delivering $125M in 2024 revenue, up from $66M in 2023
- **5 more biosimilar pipeline products**[1], added through in-licensing; Expect to launch in 2026-2027[2]

Affordable Medicines net revenue ($ millions): +8% CAGR from 2022 - 2024




(1) For the year ended March 31, 2025.
(2) Any expected launch is subject to certain assumptions and factors, many of which are out of our control, such as regulatory approval, and as such, may be subject to change. For more information, please refer to Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K.

Diversified Affordable Medicines portfolio driving sustainable growth


Purposeful Mix Shift
towards a more complex portfolio

Deep Pipeline
with focus on complex products

Affordable Medicines net revenues mix ($'s)



Pipeline mix (# of products)



Expect 20-30 new launches per year

Note: Total may not add due to rounding. Total Addressable market (TAM) are approximate IQVIA (brand + active generics) MAT Feb 2025 sales ($ in millions).

Our biosimilars portfolio is well-positioned for growth

Biosimilar Market
Next Wave of Affordable Medicines

- **Growing U.S. adoption of biosimilars** (80%+ for some molecules), similar to Europe, to improve patient access and drive cost savings
- **~$192B of branded products losing exclusivity 2024-2028**(1), including key biologics
- **Relatively limited number of players** (e.g. 10-15) given complexity, cost & development timelines, with **3-5 competitors per molecule typically**

Our Strategy
With an Expanding Portfolio

- To date, **in-licensing molecules** and leveraging commercial biosimilar business platform
- Look to **in-license additional biosimilars** to expand portfolio, targeting early to market opportunities
- **Strategic goal is to be vertically integrated** across development, manufacturing and commercial for a broad portfolio of commercial biosimilars and a cadence of new launches over time

Product name Biosimilar Biologic Brand	Therapeutic Area	U.S. Market Size ($B)(2)	Status
ALYMSYS® **Bevacizumab-maly** Avastin®	Oncology	$1.2	
RELEUKO® **Filgrastim-ayow** NEUPOGEN®	Oncology	$0.4	1st 3 biosimilars generated $125M in 2024 revenues
FYLNETRA® **Pegfilgrastim-pbbk** Neulasta®	Neutropenia	$0.8	
Denosumab Prolia®	Osteoporosis	$2.9	Q1'25 BLA filing
Denosumab XGEVA®	Bone Cancer	$1.5	Q1'25 BLA filing
Pegfilgrastim OBI & AI Neulasta®	Neutropenia	$0.8	Q3'25 sBLA filing
Omalizumab XOLAIR®	Asthma & Allergies	$2.8	Q4'25 BLA filing


Expect 6 biosimilars across 8 presentations by 2027

(1) Per IQVIA report: The Global Use of Medicines 2024: Outlook to 2028.
(2) Total U.S. net sales market size for each molecule (originator + biosimilar where applicable) in full year 2024.
Note: OBI = On-body Injector; AI = Autoinjector; BLA = Biologics License Application; sBLA = Supplemental Biologics License Application

Delivering continued double-digit growth in AvKARE segment

AvKARE Revenue by Year

+23% revenue CAGR from 2020 to 2024



Well Positioned for Long-term Growth

driven by new products and expanding channels

- Wholesaler and re-packager selling to U.S. Government agencies, clinics and hospitals with three sales channels:
  - **Government** (VA & DOD) with long-term contracts
  - **Distribution** focused on public health institutions and retail pharmacies
  - **Unit Dose** through novel re-packaging solutions

Note: Figures above exclude Amneal label products sold through AvKARE, which are included in our Affordable Medicines segment results.

Strong financial performance and reducing leverage

	FY 2022	FY 2023	FY 2024	LTM Q1 2025
NET REVENUES	$2.2B	$2.4B	$2.8B	$2.8B
ADJUSTED EBITDA(1)	$514M	$558M	$627M	$645M
GROSS DEBT	$2,740	$2,767	$2,585	$2,568
NET DEBT	$2,714	$2,675	$2,474	$2,509
GROSS LEVERAGE(2)	5.3x	5.0x	4.1x	4.0x
NET LEVERAGE(3)	5.3x	4.8x	3.9x	3.9x

- $2.3B TLB due 2028 (repaid stub in Jan. 2025)
- Credit ratings upgrade to B1 / B+ from B2 / B in 2024
- Focused on key cash uses, particularly reducing debt
- Net leverage of 3.9x as of March 2025 and expect < 3x in the next few years

(1) Adjusted EBITDA is a non-GAAP measure. Refer to the non-GAAP reconciliation in the Q1'25 earnings presentation.
(2) Gross leverage defined as gross debt divided by adjusted EBITDA. Refer to the non-GAAP reconciliation in the appendix of the Q1'25 earnings presentation.
(3) Net leverage defined as net debt divided by adjusted EBITDA. Refer to the non-GAAP reconciliation in the appendix of the Q1'25 earnings presentation

Key takeaways





Proven track record of superb execution, quality, innovation and customer service

Expanding in **high-growth areas** such as Specialty, Biosimilars & GLP-1's with significant market opportunities

Consistent high level of cash generation to invest in growth and pay down debt

Global diversified biopharmaceutical company well-positioned for **sustainable growth**



